| Medical and Health Sciences | Lifetime | 542 | ES 3 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 439 | ES 13 | 99.90 |
| Hematology | Lifetime | 9 | ES 1 | 99.96 |
| Oncology | Lifetime | 336 | ES 5 | 99.44 |
| Medical Genetics | Lifetime | 126 | ES 4 | 99.07 |
| Hematology | 2021-2025 | 8 | ES 1 | 99.84 |
| Oncology | 2021-2025 | 164 | ES 5 | 98.75 |
| Molecular Biology | 2021-2025 | 967 | ES 12 | 94.50 |
| Peptidase Inhibition and Analysis | Lifetime | 8 | ES 1 | 99.96 |
| Multiple Myeloma Research and Treatments | Lifetime | 7 | ES 1 | 99.97 |
| Protein Degradation and Inhibitors | Lifetime | 5 | ES 1 | 99.94 |
| Cancer Treatment and Pharmacology | Lifetime | 44 | ES 2 | 99.81 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 67 | ES 2 | 99.73 |
| Acute Myeloid Leukemia Research | Lifetime | 75 | ES 1 | 99.72 |
| Histone Deacetylase Inhibitors Research | Lifetime | 44 | ES 2 | 99.44 |
| Cancer therapeutics and mechanisms | Lifetime | 89 | ES 2 | 99.36 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 53 | ES 2 | 99.45 |
| Ubiquitin and proteasome pathways | Lifetime | 126 | ES 1 | 99.29 |
| Retinoids in leukemia and cellular processes | Lifetime | 66 | ES 2 | 99.12 |
| Hematological disorders and diagnostics | Lifetime | 51 | ES 1 | 98.90 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 404 | ES 3 | 99.26 |
| Hematopoietic Stem Cell Transplantation | Lifetime | 196 | ES 5 | 99.08 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 89 | ES 4 | 98.62 |
| Lymphoma Diagnosis and Treatment | Lifetime | 398 | ES 10 | 98.94 |
| Acute Lymphoblastic Leukemia research | Lifetime | 258 | ES 5 | 98.98 |
| CAR-T cell therapy research | Lifetime | 386 | ES 4 | 98.85 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 623 | ES 16 | 97.50 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 554 | ES 8 | 97.58 |
| Cancer Mechanisms and Therapy | Lifetime | 363 | ES 7 | 96.27 |
| Neutropenia and Cancer Infections | Lifetime | 636 | ES 17 | 94.94 |
| Chemokine receptors and signaling | Lifetime | 688 | ES 13 | 92.04 |
| Blood disorders and treatments | Lifetime | 859 | ES 10 | 92.12 |
| Beetle Biology and Toxicology Studies | Lifetime | 765 | ES 16 | 47.86 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 7 | ES 2 | 99.90 |
| Protein Degradation and Inhibitors | 2021-2025 | 6 | ES 2 | 99.84 |
| Peptidase Inhibition and Analysis | 2021-2025 | 13 | ES 3 | 99.56 |
| CAR-T cell therapy research | 2021-2025 | 107 | ES 5 | 99.31 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 111 | ES 4 | 98.58 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 174 | ES 10 | 96.59 |
| Cancer Treatment and Pharmacology | 2021-2025 | 193 | ES 18 | 96.19 |
| Cancer Mechanisms and Therapy | 2021-2025 | 196 | ES 5 | 89.43 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 340 | ES 11 | 86.25 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 751 | ES 28 | 79.32 |
| Viral Infectious Diseases and Gene Expression in Insects | 2021-2025 | 664 | ES 9 | 77.66 |
| Cancer therapeutics and mechanisms | 2021-2025 | 786 | ES 18 | 75.05 |
| Chemokine receptors and signaling | 2021-2025 | 286 | ES 3 | 71.35 |
